Dec 8 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Alexion Pharmaceutical Inc's treatment for a rare and potentially fatal genetic disorder.
Alexion's enzyme-replacement therapy, Kanuma, aims to treat patients with lysosomal acid lipase deficiency (LAL-D), a type of genetic disorder that often leads to multi-organ damage and premature death. (http://1.usa.gov/1QcP3qN)
Kanuma was added to the drugmaker's pipeline through its acquisition of Synageva BioPharma Corp in a deal worth $8.4 billion that closed in June.
(Reporting by Rosmi Shaji and Samantha Kareen Nair in Bengaluru; Editing by Savio D'Souza)